Medications

ALS drug gets rare second review at high-stakes FDA meeting

A closely watched experimental drug for Lou Gehrig's disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to approve the treatment for those with the fatal illness.

Medications

FDA still skeptical of ALS drug ahead of high-stakes meeting

Federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for the debilitating illness known as Lou Gehrig's disease, even as they prepare to give its drugmaker a rare second opportunity ...